Evaluation of pulmonary arterial stiffness in post mild COVID-19 patients: a pilot prospective study


Korkmaz Y., Çınar T., ŞAYLIK F., Akbulut T., Selçuk M., Oğuz M., ...Daha Fazla

Journal of Cardiovascular Imaging, cilt.32, sa.1, 2024 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 1
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1186/s44348-024-00032-3
  • Dergi Adı: Journal of Cardiovascular Imaging
  • Derginin Tarandığı İndeksler: Scopus
  • Anahtar Kelimeler: COVID-19, Pulmonary artery stiffness, Pulmonary Arterial Hypertension
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: Our primary goal was to utilize pulmonary arterial stiffness (PAS) to demonstrate the early alterations in the pulmonary vascular area in individuals with prior COVID-19 illness who had not undergone hospitalization. Methods: In total, 201 patients with prior COVID-19 infection without hospitalization and 195 healthy, age- and sex-matched individuals without a history of COVID-19 disease were included in this prospective analysis. The PAS value for each patient was calculated by dividing the mean peak pulmonary flow velocity by the pulmonary flow acceleration time. Results: The measured PAS was 10.2 ± 4.11 Hz/msec in post–COVID-19 participants and 8.56 ± 1.47 Hz/msec in healthy subjects (P < 0.001). Moreover, pulmonary artery acceleration time was significantly lower in patients with a prior history of COVID-19. Multivariable logistic regression analysis revealed that PAS was significantly connected to a prior COVID-19 illness (odds ratio, 1.267; 95% confidence interval, 1.142–1.434; P < 0.001). The optimal cutoff point for detecting a prior COVID-19 disease for PAS was 10.1 (sensitivity, 70.2%; specificity, 87.7%). Conclusions: This might be the first investigation to reveal that patients with a history of COVID-19 had higher PAS values compared to those without COVID-19. The results of the investigation may indicate the need of regular follow up of COVID-19 patients for the development of pulmonary arterial hypertension, especially during the post–COVID-19 interval.